graft-versus-host disease

(redirected from Graft-vs-host disease)
Also found in: Dictionary, Wikipedia.

graft-versus-host disease (reaction)

 (GVH disease)
a condition that occurs when immunologically competent cells or their precursors are transplanted into an immunocompromised recipient (host) that is not histocompatible with the donor. Because the host is immunocompromised, the graft is not rejected. Immunocompetent T lymphocytes derived from the donor tissue recognize the recipient's tissue as foreign or nonself and react with it, producing clinical manifestations including edema, erythema, ulceration, loss of hair, and heart and joint lesions similar to those of connective tissue disorders. This condition is a frequent complication of bone marrow transplantation. tissue typing and hla antigen matching of the donor and recipient reduce the possibility of graft-versus-host disease.

graft-versus-host disease

(grăft′vûr′səs-hōst′, -səz-)
n.
A condition in which cells from the transplanted tissue of a donor initiate an immunologic attack on the cells and tissue of the recipient.

graft-versus-host disease (GVHD)

a rejection response of certain grafts, especially of bone marrow. It is commonly associated with inadequate immunosuppressive therapy of the donor, which allows immunocompetent cells in the donated tissue to recognize the recipient's tissues as foreign and to attack them. Because the recipient is totally immunosuppressed, the recipient's immune system cannot defend against the attack. Characteristic signs may include skin lesions with edema, erythema, ulceration, scaling, loss of hair, lesions of the joints and the heart, and hemolytic anemia with a positive Coombs' test reaction. Also called graft-versus-host reaction, homologous disease.
enlarge picture
Acute graft-versus-host disease

graft-versus-host disease

Clinical immunology A reaction of donated BM against a Pt's own tissue, which is a major cause of M&M in allograft BMTs; GVHD is less significant in transplanted kidneys, heart, liver, and skin; viable donor T cells react immunologically against host Clinical Fever, morbiliform rash–central erythematous maculopapular eruption that may spread to the extremities with bulla formation, anorexia, N&V, severe watery or bloody diarrhea, lymphadenopathy, infections, hepatosplenomegaly, ↑ LFTs, jaundice, hemolytic anemia Prevention Irradiation of donated blood may prevent active leukocytes from rejecting recipient tissues Prophylaxis Cyclosporin, MTX, tacrolimus Treatment12 of Pts who develop post-BMT GVHD respond to high-dose steroids. See Bone marrow transplantation, Rapamycin, Tacrolimus, Transfusion-associated graft-versus-host disease.

graft-ver·sus-host dis·ease

(GVHD) (graft vĕr'sŭs hōst di-zēz')
An incompatibility reaction (which may be fatal) in a subject (host) of low immunologic competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor.

graft-versus-host disease

A complication usually appearing two to three weeks after a bone marrow transplantation and caused by cytotoxic T cells in the donated marrow graft. These attack the host tissues causing liver inflammation (hepatitis) with obstruction to bile flow, diarrhoea and a severe scaling skin disease called exfoliative dermatitis. Drugs such as CYCLOSPORIN (ciclosporin) and high dose steroids must be used as the condition, once fully established, has a mortality of about 30%.
graft-versus-host disease graft tissue rejection, triggered by host tissue reaction to graft antigen

graft-ver·sus-host dis·ease

(GVHD) (graft vĕr'sŭs hōst di-zēz')
An incompatibility reaction (which may be fatal) in a subject (host) of low immunologic competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor.

graft-versus-host disease

a condition that occurs when immunologically competent cells or their precursors are transplanted into an immunologically incompetent recipient (host) that is not histocompatible with the donor. Because the host is immunodeficient, the graft is not rejected. Immunocompetent T lymphocytes present in the donor tissue are activated and recognize the recipient's tissue as 'foreign' and react to them, producing clinical manifestations including edema, erythema, ulceration, loss of hair, and heart and joint lesions similar to those occurring in connective tissue disorders. Called also GVH disease or reaction, runting syndrome.
References in periodicals archive ?
Diagnostic work-up can be quite challenging given the high rate of concomitant pathologies present in these patients, including graft-vs-host disease and a wide array of opportunistic infections.
In addition, there are chapters devoted to transplantation topics, including solid-organ transplantation and hematopoietic stem cell transplantation, mononuclear cell transfusion, transfusion-associated graft-vs-host disease, and stem cell growth factors.
NASDAQ: OSIR), announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal[R] (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.
The retrospective analysis involved 220 bone-marrow transplant patients who received methotrexate, an antifolate drug used as standard therapy for preventing graft-vs-host disease, a common complication of marrow transplantation.
In addition to preventing graft-vs-host disease in marrow-transplant patients, methotrexate is used to treat certain cancers and, in lower doses, immune diseases such as rheumatoid arthritis.
Graft-vs-host disease -- a complication associated with blood and bone marrow transplants
Although anti-tumor responses were seen in 33% of evaluable patients with blood cancers that had not responded to other treatments, most of these patients developed acute Graft-vs-Host Disease (GvsHD).
The INTERCEPT Blood System has received CE mark approvals for both the platelet and plasma systems, and may replace gamma irradiation for protection against transfusion-associated graft-vs-host disease.
DOR's lead product, orBec(R) (oral beclomethasone dipropionate), has recently completed enrollment in a multicenter, pivotal phase III clinical trial for the treatment of acute intestinal graft-vs-host disease, a form of serious and life-threatening gastrointestinal inflammation.
The Company's development pipeline includes: a drug candidate that controls cell proliferation and nutrient uptake by tumors to treat cancer; a bone-targeted drug candidate to treat the complications of cancer that has spread to bone; a regulated protein therapy product candidate to treat anemia in which the production of erythropoietin is controlled in vivo using an orally administered drug; a T cell immunotherapy product candidate in which a non-immunosuppressive drug may be used to treat graft-vs-host disease following donor bone marrow transplantation - a therapy for cancer and other immune and blood diseases; and dual-action drug candidates that block bone resorption and stimulate bone formation to treat osteoporosis.
Nasdaq: ARIA) today announced development of new clinical-scale methods for producing large numbers of therapeutic engineered donor T cells - an important milestone in the phase 2 development of the Company's product candidate to treat graft-vs-host disease.
Total expenses for the first quarter of 2002 were slightly lower than those for the fourth quarter of 2001, reflecting our vigorous efforts to prudently manage expenditures and yet to advance three of our hematology and oncology product candidates towards IND filings and our product candidate for graft-vs-host disease in phase 2 development," said Harvey J.